No Evidence for Statin-induced Proteinuria in Healthy Volunteers as Assessed by Proteomic Analysis by Verhulst, Anja et al.
Hindawi Publishing Corporation
Journal of Biomedicine and Biotechnology
Volume 2011, Article ID 456076, 9 pages
doi:10.1155/2011/456076
Research Article
No Evidencefor Statin-induced Proteinuriain Healthy Volunteers
as AssessedbyProteomicAnalysis
Anja Verhulst,Hilde Geryl,and PatrickD’Haese
Laboratory of Pathophysiology, University of Antwerp, Universiteitsplein 1, 2610 Antwerpen, Belgium
Correspondence should be addressed to Patrick D’Haese, patrick.dhaese@ua.ac.be
Received 21 April 2011; Revised 14 June 2011; Accepted 4 July 2011
Academic Editor: Yeon-Kyun Shin
Copyright © 2011 Anja Verhulst et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
In clinical studies of statins (class of drugs lowering plasma cholesterol levels), transient low-molecular-weight proteinuria was
observed. The causes of statin-induced proteinuria in the patient background of those studies (cardiovascular and kidney disease)
are multifactorial and, therefore, a matter of debate. In light of this, it seemed interesting to investigate the eﬀect of statins
on the urinary protein concentration and proteome in healthy volunteers. Six healthy volunteers were randomly treated with
rosuvastatin (40mg/day) or pravastatin (80mg/day) in a double-blinded cross-over study. Total urinary protein concentration
and the concentration of albumin/retinol-binding protein were analysed, after which the urinary proteome was investigated.
From the results described in this study, it was concluded that statins do not induce major changes in the urinary protein
concentration/proteome. High variability in the baseline urinary proteome/proteins among volunteers, however, made it very
diﬃcult to ﬁnd subtle (possibly isolated to individuals) eﬀects of statins.
1.Introduction
Statins,bytheirabilitytoinhibit3-hydroxy-3-methylglutaryl
coenzyme A (HMG-CoA) reductase, the rate-limiting
enzyme of the sterol pathway, are potent inhibitors of sterol
biosynthesis [1]. As a result of the reduction of cellular sterol
pools, there is compensatory upregulation of cell-surface
receptorsforcholesterol-containing-lowdensitylipoproteins
(LDL), an eﬀect that takes place mainly in the liver [2–4].
This mechanism underlies the therapeutic use of the statins
to lower plasma cholesterol and particularly the levels of
LDL. However, many additional eﬀects of statins on cell
function have been described in the literature [5]. These
appear to be independent of cellular cholesterol homeostasis
and are collectively termed “pleiotropic eﬀects”. Many of
these have been shown to result from the depletion of
mevalonate- (the HMG-CoA conversion product) derived
intermediates of the sterol pathway, particularly the iso-
prenoid pyrophosphates such as geranylgeranyl pyrophos-
phate (GGPP). Isoprenoid pyrophosphates are required by
the cells for the posttranslational modiﬁcation of a range of
proteins, especially GTP-binding proteins.
In phase III studies of rosuvastatin, which included com-
parative studies with other statins and placebo, proteinuria
was observed in some subjects, most frequently in those
taking rosuvastatin at the 80mg dose (above the approved
dose range of 5 to 40mg). The proteinuria observed with
rosuvastatin was generally transient, not associated with
worsening renal function, and mainly of tubular type,
suggestingreducedreabsorptionofnormallyﬁlteredproteins
of low molecular weight [6–8]. This was further supported
by results obtained in (human and opossum) renal epithelial
cell cultures, in which receptor-mediated endocytosis could
be inhibited by statins. Moreover, this eﬀect could be
prevented by the addition of mevalonate and GGPP but not
cholesterol [9, 10]. The mechanism underlying this reduced
rate of protein reabsorption was linked to inhibition of
HMG-CoA reductase in the proximal tubule cells which in
turn leads to a depletion of the cellular GGPP pool and
thereby to reduced function of one or more GTP-binding
proteins, known to be involved in the process of endocytosis
[10–13].
To further explore the clinical relevance of these ﬁndings,
the possible eﬀect of statin treatment on the urinary protein
composition of healthy volunteers randomly treated with
the currently permitted doses of rosuvastatin (40mg/day) or
pravastatin (80mg/day) was studied in a blinded cross-over2 Journal of Biomedicine and Biotechnology
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Figure 1: Schematic overview of the study setup.
study.Bothpravastatinandrosuvastatinhaveahigherdegree
of renal secretion than the other marketed statins [14]. In
the ﬁrst instance, the total urine protein concentration and
the concentration of albumin and retinol-binding protein
in urine were analysed as accepted indices of the eﬀect
of the statins on tubular reabsorption of urinary proteins.
Subsequently, the urinary proteome was investigated by two-
dimensional gel-electrophoresis-based proteomics in order
to investigate possible statin-induced eﬀects on proteinuria
in more detail.
2.MaterialandMethods
2.1. Study Setup and Urine Sampling. A blinded comparator
cross-over study was performed (see Figure 1). Mid-stream
morning urine was collected from 6 healthy volunteers
(inclusion/exclusion criteria see Table 1) during two con-
secutive periods of 13 days, during which volunteers were
treated (for 5 days) with a statin (rosuvastatin 40mg/day;
pravastatin: 80mg/day) between 9 and 11pm. Volunteers
were recruited prospectively and started the study at the
same moment. For 2D DIGE (2-D Fluorescence Diﬀerence
Gel Electrophoresis) analysis, a number of 4 biological
replicates is recommended in general. Since we were aware
of the relatively high biological variation of proteinuria
(both inter- and intravolunteer), we opted to work with
2 extra replicates (6 instead of 4 volunteers). A 2-week
wash-out period without urine sampling was included
between the two treatment periods. Three volunteers ﬁrst
receivedrosuvastatinfollowedbytreatmentwithpravastatin,
while the other three volunteers ﬁrst underwent pravastatin
treatment followed by rosuvastatin. Statin treatment started
atday4andendedatday8ofeachurinecollectionperiod.In
this way, the statin treatment period was preceded by a 3-day
(days 1–3) pretreatment period and followed by a 5-day oﬀ
statin treatment period (days 9–13).
Urine samples consisted of fasting morning mid-stream
urine which was collected in a sterile recipient already
containing a protease-inhibitor tablet (Complete, Roche).
The samples were stored by the participants in cool boxes
and transported to the lab within 3h after collection. Upon
arrival, the samples were aliquoted in 3 fractions and stored
at −80◦C: two 10mL aliquots were used for biochemical
analysis and the remaining volume for proteome analysis.
Urine samples for proteome analysis were ﬁrst prepared
for CyDye labeling (see Section 2.3.1), after which they
were pooled per volunteer and per treatment period as
follows: before-treatment sample (samples of days 1 to 3),
during-treatment sample (samples of days 7 to 9), and after-
treatment sample (samples of days 11 to 13). Sample pooling
resulted in a total of 36 samples (6 samples per volunteer).
Samples of day 4, 5, 6, and 10 were not used for further
analysis.
Informed consent of all 6 volunteers was obtained.
Furthermore, this study was approved by the ethical com-
mittee of the Antwerp University Hospital, carried out in
accordance with the code of ethics of the world medical
association for experiments involving humans (declaration
of Helsinki) and registered to EUDRACT.
2.2. Biochemical Urine Analysis. Urinary creatinine was
determined by a colorimetric method (Creatinine Merck-
otest, Diagnostica Merck) based on Jaﬀe’s method. Urinary
protein content was measured using the Bradford method.
Urinary microalbuminuria was analysed by nephelometry,
using N-antiserum to human albumin. Finally, urinaryJournal of Biomedicine and Biotechnology 3
Table 1: Inclusion and exclusion criteria of the study.
Inclusion criteria Exclusion criteria
Male Treatment with lipid-lowering drugs <1 year prior to the study
Age 25–65 years Known history of diabetes or fasting glucose level >110mg/dL
Nonsmoker Antihypertensive medication
Proteinuria <150mg/24 hours Lifeexpectancy <1 year
Dipstick negative hematuria Pharmacological treatment with inotropes
Blood pressure <135mm systolic, <85mm
diastolic
Acute or chronic inﬂammatory process, use of anti-inﬂammatory drugs, or
immunosuppression
Waist circumference <94cm Clinically active malignant disease
Administration of any investigational drug within 30 days preceding the study
start and during the study
Known intolerance to rosuvastatin or other statins
Acute or chronic liver disease or ALAT >2.0 × upper limit of normal (ULN) at
enrolment visit.
Chronic muscle disease such as dermatomyositis or polymyositis or unexplained
creatinine kinase (CK) above 3 × ULN at enrolment
Uncontrolled hypothyroidism as indicated by a thyroid-stimulating hormone
(TSH) >2 × ULN at enrolment
Renal insuﬃciency: creatinine >2.0mg/dL
Known or suspect alcohol or drug abuse
retinol-binding protein concentration was determined using
an ELISA-based method at the Laboratory of Toxicology of
the University Hospital St-Luc, Brussels, Belgium.
2.3. Urinary Proteome Analysis Using 2D Fluorescence
Diﬀerence Gel Electrophoresis (DIGE) Technology
2.3.1. Sample Preparation for CyDye Labeling. One hundred
and eight urine samples (18 samples of 6 volunteers, see
Section 2.1) were prepared for CyDye labeling. Urine sam-
ples were thawed at 25◦C and centrifuged at 4◦Cf o r1 0m i n
at 3000rpm. Protein concentration was determined in the
supernatant using the method of Bradford. Subsequently,
the supernatant (no more than the volume corresponding to
1mg of protein) was dialysed using dialysis membranes with
a cut-oﬀ value of 3500Da and polyethylene glycol 35000.
After overnight dialysis at 4◦C, the membranes were put
in MQ H2O for 15min. The protein concentration of the
remainingsolutioninthedialysismembranewasdetermined
using the 2D quant kit (GE Healthcare) after which the
2D clean-up kit (GE Healthcare) was used to prepare the
sample (150μg of protein) for CyDye labeling. The protein
concentration was determined again using the 2D quant kit.
Finally, the pH of the sample was determined. All samples
had a pH of 8.2 which fell within the allowed range of 7.0 to
9.4.
2.3.2. Pooling of the Samples. The 108 prepared samples
were pooled per 3 samples (per volunteer and per treatment
period, see Section 2.1), resulting in 36 pooled samples.
Sample pooling was performed so that each of the 3 samples
was equally present in the pooled sample, and resulted in a
50μg protein sample. In addition, a pool of the 36 pooled
samples was prepared which served as internal standard.
2.3.3. CyDye Labeling. The 36 pooled samples were labeled
with Cy3 or Cy5. The internal standard was labeled with
Cy2. CyDye(Cy2,Cy3,andCy5,GE Healthcare)labeling was
performed following manufacturer’s instructions.
2.3.4. First Dimension (Isoelectric Focusing). The 36 Cy3- or
Cy5-labeledsampleswereloadedonto18isoelectricfocusing
strips (Immobiline DryStrip with nonlinear pH gradient 3–
10, GE Healthcare). Hereto each Cy3-labeled sample (50μg)
was at random added to a Cy5-labeled sample (50μg) and
to 50μg of the Cy2 labeled internal standard. Subsequently, a
mixture of 500μLr e h y d r a t a t i o nb u ﬀer (7M urea, 2M thio-
urea, 1.5% CHAPS, 260mM DTT and pharmalytes) and the
Cy3-, Cy5-, and Cy2-labeled proteins was equilibrated for 6
hours on the isoelectric focusing strips. Isoelectric focusing
wasperformedsubsequentlyovernight,afterwhichthestrips
were frozen at −80◦C.
2.3.5. Second Dimension. Frozen strips were thawed and
equilibrated for 20min in 50mM Tris-HCl buﬀer, pH 6.8,
ureum 6M, SDS 2%, and DTT 1%, followed by a further
20min. equilibration in the same buﬀer with the exception
that DTT 1% was replaced by iodoacetamide 4%. For the
second dimension, 12.5% polyacrylamide gels were used.
2.3.6. Gel Scanning and Analysis. Gels were scanned on the
Typhoon scanner (GE Healthcare) at 3 diﬀerent excitation
wavelengths: 488, 532 and 633 appropriate for Cy2, Cy3, and
Cy5, respectively.4 Journal of Biomedicine and Biotechnology
Analysis of the gels (each gel contains 3 spot maps, a
Cy2-, a Cy3- and a Cy5-labeled), including the statistical
analysis, was performed using ImageQuant and Decyder
software (GE Healthcare). Spot protein identiﬁcation was
not a part of this study since statistical analysis of spot
maps was not able to identify any protein with statistically
signiﬁcant expression in the diﬀerent treatment groups.
3. Results
3.1.BiochemicalUrineAnalysis. Theurinaryproteincontent,
microalbuminuria, and retinol-binding protein concentra-
tion were calculated per mg creatinine. A substantial vari-
ation was noticed for all three parameters, both with time
in the same volunteer as among volunteers. However, all
measurements of the three parameters fell within the normal
range of these parameters. Also, no signiﬁcant eﬀect of statin
treatment on any of these parameters could be observed
(Figure 2).
3.2. Proteome Analysis
3.2.1. Assessment of Outlying Spot maps. In order to detect
outlying spot maps that should be excluded for further
analysis,principalcomponentanalysisofthe36spotmaps(6
spot maps of 6 volunteers) was performed. Since no outlying
spot maps could be detected (see Figure 3), all 36 spot maps
were included for further analysis.
3.2.2. Spot Detection. An average of 1852 ± 244 spots were
detected on the spot maps. A master gel containing 1752
spots was chosen. Statistical analysis was performed on 965
spots (spots present on at least 70% of the spot maps).
3.2.3. General Eﬀect of Statins on the Urinary Proteome. To
check for a general eﬀect of the statins under study on the
urinary proteome, both principal component analysis and
diﬀerential expression analysis were performed. Principal
component analysis did not reveal any eﬀect. Indeed, as
demonstrated in Figure 4, no clustering of spot maps from
either the “during-treatment period” or “before-” or “after-
treatment” periods was observed. Diﬀerential expression
analysis (one-way ANOVA and Student’s t-test, based on
both paired and nonpaired statistics), with correction for
multiple comparisons, also was not able to identify proteins
that were diﬀerentially expressed as a result of statin
treatment.
3.2.4. Inter- Versus Intravolunteer Variance. Principal com-
ponentanalysisofthespotmapsofdiﬀerentvolunteersmade
clearthatspotmapsofthesamevolunteerstoacertainextent
clustered (Figure 5). This could further be evidenced using
hierarchical clustering analysis and diﬀerential expression
analysis. Indeed, one-way ANOVA analysis, with correction
for multiple comparisons, detected 276 (out of 965) proteins
to be diﬀerentially expressed between volunteers with a P
value <0.01 and 43 proteins (out of 965) to be diﬀerentially
expressed between volunteers with a P value <0.001.
The fact that there was some clustering of spot maps in
the individual volunteers indicates that the spot maps of a
particular individual volunteer have more in common with
each other than with the spot maps of other volunteers.
In other words, the intervolunteer variance was higher
compared with the intravolunteer variance. This prompted
us to investigate a possible statin-induced eﬀect in the
diﬀerent volunteers separately.
3.2.5. Intravolunteer Eﬀect of Statins. Figure 5 clearly shows
partial clustering of spot maps originating from one and the
same volunteer. It was remarkable that nonclustering spot
maps in most cases originated from the “during-treatment”
period. In fact this was the case in 4 of the 6 volun-
teers. Figure 6 shows examples of nonclustering “during-
treatment” spot maps. This intravolunteer approach, how-
ever,doesnotallowstatisticalanalysis.Therefore,theanalysis
investigating the general eﬀect in all volunteers was repeated,
excluding the volunteers and treatment periods for which
the “during-treatment” spot maps clustered (overlapped)
with the “before-” and “after-” treatment spot maps.
Principal component analysis showed partial clustering of
the “during-treatment” spot maps (Figure 7). Diﬀerential
expression analysis of these spot maps, however, did not
identify statin-induced statistically signiﬁcant diﬀerences in
protein expression. A limited list of proteins with borderline
signiﬁcantlydiﬀerentexpressionduringthetreatmentperiod
lost signiﬁcance when a correction for multiple comparison
(false discovery rate correction) was made.
3.2.6. Eﬀects of Diﬀerent Treatment Arms. In order to sep-
arate the possible eﬀects of the two diﬀerent statins from
each other we performed principal component analysis of
the “during-treatment” spot maps of the two diﬀerent statins
under study (Figure 8). No statin-dependent clustering of
spot maps could be observed.
This analysis was repeated, excluding the volunteers and
treatment periods for which the “during-treatment” spot
maps clustered with the “before-” and “after-” treatment
spot maps. Again, this resulted in the absence of any
statisticallysigniﬁcantdiﬀerencebetween“during-,”“before-
,” and “after-treatment” spot maps for the two statins under
study after correction for multiple comparison.
4. Discussion
The reported eﬀects of statins on the kidney and the urinary
protein concentration is multifactorial and, therefore, a
matter of debate. Out of these discussions, one may conclude
that the eﬀect of statins on proteinuria is dual. (1) Patients
treated with statins often suﬀer from underlying chronic
kidney disease. Post hoc analysis of major statin trials
(ﬁrst endpoints were related to cardiovascular diseases) as
well as meta-analyses of small randomized controlled trials
suggest that statins reduce proteinuria and the rate of decline
of glomerular ﬁltration rate (for review see [15]). It was
necessary to perform the current study in healthy volunteers
whicharefreeofthisphenomenon,sinceitwouldcomplicateJournal of Biomedicine and Biotechnology 5
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Figure 2: Quantiﬁcation of proteins (a, b), microalbuminuria (c, d), and retinol binding protein (e, f) in urine. (a, c, e): mean values
(and SD) of the urinary protein content of diﬀerent volunteers and diﬀerent treatment periods. (b, d, f): Urinary protein content of one
representative volunteer during one-treatment period.
the investigation of a second phenomenon, completely
unrelated to this but which we wanted to investigate. (2)
This second phenomenon consists of the observation that
statins, particularly at high doses, may increase proteinuria.
As already described in the Introduction, this was observed
during the preapproval studies of rosuvastatin: patients
with the high 80mg dose exhibited a higher incidence of
proteinuria on dipstick analysis compared with controls
not receiving the compound. However, this increase in
proteinuria was transient, did not lead to acute kidney injury
or aggravate kidney failure [16], and was not associated with
later development of renal impairment or renal failure [17].
The mechanism underlying this transient proteinuria
was investigated in vitro in our laboratory and found to6 Journal of Biomedicine and Biotechnology
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Figure 3: Principal component analysis of the 36 spot maps,
representingthe36samplesoriginatingof6volunteers.Nooutlying
spot maps could be identiﬁed.
10 8 6 4 2 0 −2 −4 −6 −8 −10
PC1
−5
−4
−3
−2
−1
0
1
2
3
4
5
P
C
2
Before
During
After
Figure 4: Principal component analysis of “before” “during,” and
“after-treatment” spot maps. No clustering of spot maps can be
observed for any if the 3 conditions.
be related to reduced proximal tubular protein endocytosis
because of proximal tubular mevalonate depletion and
reduced protein geranylgeranylation [9].
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Figure 5: Principal component analysis of spot maps originating
from diﬀerent volunteers. Spot maps of the same volunteer to a
certain extent cluster (ovals).
In line with this, it was observed that patients with
primary hyperlipidemia taking rosuvastatin 10 or 20mg/day
for 12 weeks showed a concentration-dependent increase in
the urinary α-1 microglobulin (a urinary low-molecular-
weight protein) excretion of 17.6 and 34.9%, respectively
[18].
One may speculate about the clinical eﬀect of statin-
induced inhibition of proximal tubular protein endocytosis.
Overload of tubular cells with ﬁltered proteins due to
increased glomerular permeability as seen in progressive
nephropathies has been put forward as the most important
mechanism that translates glomerular protein leakage into
tubular signals of interstitial inﬂammation and ﬁbrosis [19–
22]. In light of this, it may be speculated that statin use
may be associated with less tubulointerstitial inﬂammation
and ﬁbrosis. Indeed, an in vitro study of Chana et al. made
clear that statins are able to attenuate albumin-mediated
chemokine production by proximal tubular cells. To induce
this reduction; however, it was insuﬃcient to inhibit the
endocytosis of albumin alone [23]. Nonetheless, these results
arecongruentwiththeknownpleiotropicanti-inﬂammatory
actions of statins that are independent of lipid-lowering
eﬀects but largely dependent upon inhibition of NFκB[ 24,
25]. Overall, the ﬁnal outcomes of anti-NFκB actions of
statins are similar to their inhibiting eﬀect on endocytosis
and are also related to mevalonate depletion and reduced
protein geranylgeranylation [26, 27].
Altogether, these observations encouraged us to investi-
gate the eﬀect of statin treatment on the urinary proteome,
next to the measurement of the total urinary proteinJournal of Biomedicine and Biotechnology 7
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Figure6:Principalcomponentanalysisofbefore-,during-andafter-treatmentspotmapsof2diﬀerentvolunteers(representativeexamples).
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Figure 7: Principal component analysis of “before-”, “during-” and
“after-treatment” spot maps. Partial clustering (red oval) of during-
treatment spot maps can be observed.
and retinol-binding protein (low-molecular-weight protein)
excretion in healthy volunteers, that is, without underlying
kidney disease.
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Figure 8: Principal component analysis of during-treatment spot
maps originating from the two diﬀerent statins: pravastatin (statin
A) and rosuvastatin (statin B).
From the results described in this study, it could be
concluded that statins do not induce important changes
in the urinary protein concentration/proteome of healthy8 Journal of Biomedicine and Biotechnology
volunteers. High variability in the baseline urinary pro-
teome/proteins among volunteers, however, made it diﬃcult
to demonstrate distinct eﬀects of statins. On the other
hand, the fact that “during-treatment” spot maps of 4 of
the 6 volunteers did not cluster with the “before-” and
“after-” treatment spot maps when principal component
analysis was performed, suggests that statins may exert
subtle eﬀects on the urinary proteome of some volunteers.
Because of the limited number of subjects included in the
current project (which was inherent to the currently used
proteome analysis) and the above-described high variability
inbaselineproteome, thiscouldnot unequivocallybeproven
statistically.
Also, one cannot exclude the possibility that administra-
tion of a higher statin dose (rosuvastatin 80mg/day instead
of 40mg/day) would have been necessary to induce a distinct
eﬀect on the protein concentration/proteome changes. At
rosuvastatin doses ≤40mg/day, the rate of dipstick positive
proteinuria was within the range observed with other statins
and, notably, placebo. However, administration of rosuvas-
tatin at the 80mg/day dose is not approved, and treating
healthy volunteers at this dose is not ethically permissible.
Because dipstick analysis (as used during the rosuvastatin
phase III trials in which proteinuria was detected) is a
highly insensitive measure for proteinuria; however, it was
hopedthatthegreatersensitivityofproteomicswouldenable
characterization of more subtle (subclinical) eﬀects induced
by statins at lower doses. In this context, it is also worth
mentioning that few patients treated with rosuvastatin at
40mg/day (2%) and a greater proportion of patients treated
with 80mg/day (33%) achieved a steady-state plasma drug
concentration (<50ng/mL), suggesting a potential threshold
in the drug level at which the risk for distinct proteinuria
is increased [14]. Although we expected to observe possible
statin-induced eﬀects already after a short treatment period,
it is also possible that longer treatment periods are necessary
toinducedistincteﬀects.However,itwasalsonotallowedfor
ethical reasons to treat healthy volunteers for longer periods
with the high (highest allowed) statin doses.
In general, it can be concluded that short-term statin
treatment with the highest allowed doses in healthy volun-
teers does not induce major changes in the urinary protein
concentration/proteome.
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